These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22918162)

  • 1. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency.
    Shia J; Zhang L; Shike M; Guo M; Stadler Z; Xiong X; Tang LH; Vakiani E; Katabi N; Wang H; Bacares R; Ruggeri J; Boland CR; Ladanyi M; Klimstra DS
    Mod Pathol; 2013 Jan; 26(1):131-8. PubMed ID: 22918162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
    Shia J; Stadler Z; Weiser MR; Rentz M; Gonen M; Tang LH; Vakiani E; Katabi N; Xiong X; Markowitz AJ; Shike M; Guillem J; Klimstra DS
    Am J Surg Pathol; 2011 Mar; 35(3):447-54. PubMed ID: 21297438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
    Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
    Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas.
    Mojtahed A; Schrijver I; Ford JM; Longacre TA; Pai RK
    Mod Pathol; 2011 Jul; 24(7):1004-14. PubMed ID: 21499234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.
    Shia J; Tang LH; Vakiani E; Guillem JG; Stadler ZK; Soslow RA; Katabi N; Weiser MR; Paty PB; Temple LK; Nash GM; Wong WD; Offit K; Klimstra DS
    Am J Surg Pathol; 2009 Nov; 33(11):1639-45. PubMed ID: 19701074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
    Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
    Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer.
    Montazer Haghighi M; Radpour R; Aghajani K; Zali N; Molaei M; Zali MR
    Int J Colorectal Dis; 2009 Aug; 24(8):885-93. PubMed ID: 19479271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
    Kaur G; Masoud A; Raihan N; Radzi M; Khamizar W; Kam LS
    Indian J Med Res; 2011 Aug; 134(2):186-92. PubMed ID: 21911971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-level microsatellite instability in appendiceal carcinomas.
    Taggart MW; Galbincea J; Mansfield PF; Fournier KF; Royal RE; Overman MJ; Rashid A; Abraham SC
    Am J Surg Pathol; 2013 Aug; 37(8):1192-200. PubMed ID: 23648460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
    Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
    Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch repair deficiency screening via immunohistochemical staining in young Asians with colorectal cancers.
    Chew MH; Koh PK; Tan M; Lim KH; Carol L; Tang CL
    World J Surg; 2013 Oct; 37(10):2468-75. PubMed ID: 23887594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer.
    Truninger K; Menigatti M; Luz J; Russell A; Haider R; Gebbers JO; Bannwart F; Yurtsever H; Neuweiler J; Riehle HM; Cattaruzza MS; Heinimann K; Schär P; Jiricny J; Marra G
    Gastroenterology; 2005 May; 128(5):1160-71. PubMed ID: 15887099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 19. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting.
    Overbeek LI; Ligtenberg MJ; Willems RW; Hermens RP; Blokx WA; Dubois SV; van der Linden H; Meijer JW; Mlynek-Kersjes ML; Hoogerbrugge N; Hebeda KM; van Krieken JH
    Am J Surg Pathol; 2008 Aug; 32(8):1246-51. PubMed ID: 18677806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer.
    South CD; Yearsley M; Martin E; Arnold M; Frankel W; Hampel H
    Genet Med; 2009 Nov; 11(11):812-7. PubMed ID: 19752738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.